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Synthetic cannabinoids (SCs) are a group of new psychoactive drugs used recreationally
with potential health risks. They are monitored by the EU Early Warning System since 2010
due to severe adverse effects on consumers. JWH-122 and JWH-210 are naphthoylindole
SCs and potent cannabinoid receptor CB1 and CB2 agonists. Information about the
effects of SCs usually is available from intoxication cases and surveys, and few studies on
humans after controlled administration or observational/naturalistic studies using
standardized measures of cardiovascular and subjective effects are available. The aim
of this study was to evaluate the acute pharmacological effects of JWH-122 and JWH-210
recreational consumption in a 4 h observational study and assess their disposition in oral
fluid (OF). Sixteen volunteers self-administered 1mg dose of JWH-122 (n  8) or 2.25 mg
mean dose of JWH-210 (range 2–3mg, n  8) by inhalation (smoking). Physiological
parameters including blood pressure (systolic and diastolic), heart rate (HR), and
cutaneous temperature were measured. A set of visual analog scales, the 49-item
short-form version of the Addiction Research Center Inventory (ARCI), and the
Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE)
were used for the evaluation of subjective effects. OF was collected at baseline and at 10,
20, and 40min and 1, 2, 3, and 4 h after self-administration. Statistically significant
increases in systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR
were observed after JWH-122 self-administration but not after JWH-210 self-
administration. JWH-210 self-administration produced significant changes in subjective
drug effects, similar to those induced by THC (intensity, high, good effects, and hunger).
The subjective effects following JWH-122 consumption were minimal. The maximal effects
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were mostly observed 20min after intake. JWH-122 and JWH 210 OF concentration
reached a peak 20 min after administration and could not be detected after 3 h. The results
demonstrated a different pattern of effects of these two SCs. Due to the limitations of our
observational study, further research with a larger sample and controlled studies are
needed to better define the acute pharmacological effect and health risk profile of JWH-
122 and JWH-210.
Keywords: JWH-122, JWH-210, synthetic cannabinoid receptor agonists (SCRAs), physiological effects, subjective
effects
INTRODUCTION
Synthetic cannabinoids (SCs), also known as “synthetic
cannabinoid receptor agonists” (SCRAs), are a chemically
diverse group of small nonpolar and lipid-soluble molecules
functionally similar to delta-9-tetrahydrocannabinol (THC) with
a higher binding affinity for cannabinoid receptors CB1 and CB2
than that of natural cannabinoids, such as THC (Huffman et al.,
2003; Huffman et al., 2005). Initially, many SCs were developed for
research purposes to investigate the endocannabinoid system or as
potential therapeutic drugs. More recently, SCs have been diverted
for recreational purposes, and new molecules emerged (Pertwee,
2006). SCs usually are named after the scientist/institution/
company who first synthesized (JWH, CP, HU, AM, WIN, and
RCS series) the substance or take names helping their marketing.
From the early 2000s, SCs were introduced onto the drugmarket as
“legal highs,” “herbal incense,” “K2,” or “Spice” as a legal alternative
to natural cannabis (ElSohly et al., 2014; Kemp et al., 2016; Ernst
et al., 2011). Currently, SCs are the largest and most structurally
diverse class of new psychoactive substances (NPS) seized in
Europe, with at least 190 substances monitored by the EU Early
Warning System since 2010 (European Monitoring Centre for
Drugs and Drug Addiction and Europol, 2019; European
Monitoring Centre for Drugs and Drug Addiction, 2020).
Due to their high affinity for the CB1 receptor (Huffman et al.,
2005), SCs usually are more potent than natural cannabinoids,
with potential health risks. The pattern of acute clinical toxicity
associated with the recreational use of SCs is frequently
characterized by tachycardia, agitation, and nausea, which
typically resolve with symptomatic care (Cohen et al., 2019;
Tournebize et al., 2017; Hermanns-Clausen et al., 2013). In
some cases, severe toxicity including stroke, seizure,
myocardial infarction, rhabdomyolysis, acute kidney injury,
psychosis, suicidal ideation, and hyperemesis has been
associated with SCs use, and SCs have been directly or
indirectly involved in fatal cases (Hermanns-Clausen et al.,
2013; Tait et al., 2016).
JWH-122 and JWH-210 are naphthoylindolic compounds and
act as potent cannabinoid agonists at CB1 and CB2 receptors.
According to a structure-activity relationship study, JWH-122
and JWH-210 have a binding affinity at cannabinoid CB1
receptors 60 and 90 times higher than that of THC,
respectively. JWH-122 and JWH-210 CB2 receptors’ affinity is
30 and 50 times higher than that of THC, respectively (Huffman
et al., 2003; Huffman et al., 2005).
Recently, a rise in the recreational use of extremely potent SCs
such as JWH-122 and JWH-210 has been reported (La Maida
et al., 2020). To date, the recreational use of JWH-122 and/or
JWH-210 has been analytically documented in several cases of
driving under the influence (DUI) and nonfatal and fatal cases
(Yeakel and Logan, 2013; Dziadosz et al., 2014; Musshoff et al.,
2014; Tuv et al., 2014). Hallucinations, disorientation, agitation,
tachycardia, and/or hypertension in intoxication cases involving
JWH-122 have been described (Coppola et and Mondola, 2017).
Most data of the pharmacological effects are based on surveys
and series or cases of acute intoxications (Hermanns-Clausen
et al., 2013; Hermanns-Clausen et al., 2016). There is a lack of
studies in humans evaluating the acute pharmacological effects of
SCs in experimental or observational controlled settings
(Theunissen et al., 2018; La Maida et al., 2021). New
controlled research is needed to understand the complex
pharmacological effects of this group of substances.
The aim of this study was to evaluate the acute
pharmacological effects and time course (TC) concentrations




Sixteen healthy subjects participated in the study. Eight subjects
(one female and seven males) self-administrated JWH-122 and
eight subjects (three females and five males) self-administrated
JWH-210. Participants were recreative drug users and had used
cannabis and SCs at least once in their lifetimes without
experiencing serious adverse reactions. Exclusion criteria were
history of any serious medical or mental disorder including drug
dependence (except for nicotine), use of chronic medication, and
serious adverse reactions with cannabis and/or SCs. Subjects were
recruited through word-of-mouth and snowball sampling via the
nongovernmental Organization Energy Control (ABD). The
study protocol was submitted and approved by the Clinical
Research Ethics Committee of our center, Germans Trias i
Pujol University Hospital (CEI HUGTiP, Barcelona, Spain; ref.
PI-18-267), and was conducted according to the Declaration of
Helsinki recommendations. All the participants were correctly
and fully informed, both orally and in writing, of the purpose,
methods, and means of the study. All the subjects agreed to
participate in the study and signed informed consent prior to
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inclusion. Participants received monetary compensation for their
participation.
Study Design and Treatments
The study design was naturalistic, prospective, and observational,
with minimal intervention. The self-selected dose of JWH-122 or
JWH-210 was mixed with 1 g tobacco and prepared as a joint. The
participants had a maximal time of 5 min to smoke the joint
following the subject usual habits of consumption (3–4.5 min,
10–11 inhalations). The mouth of the participants was washed
with plain water to reduce contamination that could interfere with
OF sampling (de Castro et al., 2014). All the doses that were self-
administrated were also self-selected by each participant based
presumably on their previous experience. Subjects brought their
powder of SCs to the testing site themselves, which they had
obtained from an unknown source. Although no information was
available about the synthesis of the drug, those samples were tested
by Energy Control, a harm reduction organization that provides a
Drug Checking Service for users. The JWH-122 and JWH-201
contents were analyzed with gas chromatography associated with
mass spectrometry (GC/MS) and showed that the substance purity
was more than 95% with no toxic adulterants. The absence of the
most common drugs of abuse including cocaine, MDMA,
amphetamine, methamphetamine, 2C-B, other phenethylamines,
heroin, LSD, DMT, other tryptamines, ketamine, psilocybin,
salvinorin A, natural, SCs, and most of the NPS was analytically
confirmed (Grifell et al., 2017; Graziano et al., 2019). The dose of
JWH-122 and JWH-210 was selected after reviewing the literature
and drug users fora (Hermanns-Clausen et al., 2013; Tournebize
et al., 2017). Similar doses were reported in JWH-122 and JWH-
210 users by Energy Control, which recommends subjects to take
from 1mg JWH-122 and 2–3 mg JWH-210 to avoid possible
health risks.
The mean JWH-122 dose was 1 mg (all subjects self-
administrated 1 mg, n  8) and the mean JWH-210 dose was
2.25 mg (onemale and one female self-administrated a 3 mg dose,
and four males and two females self-administrated 2 mg).
Procedures
All participants underwent a general medical examination and a
psychiatric evaluation prior to the study sessions. They received
training to fill the questionnaires and follow the procedures
employed in the study. Sessions took place at a private club
with ambient music, and participants could talk, read, or play
table games and interact during the sessions, but not during the
evaluation time. Sessions were planned on two different days,
each day for one of the two groups of volunteers per substance.
On the day of the session, subjects were admitted to the selected
recreational venue and they were questioned about any event that
could impede their participation. They were asked to refrain from
taking drugs two days prior to the session, and alcohol
concentrations in expired air were measured before the
beginning of the sessions. Assessments were performed at
baseline (before dose) and at 10, 20, and 40 min and 1, 2, 3,
and 4 h after self-administration. Urine spot samples were
collected prior to the administration, to exclude substance
drug use (benzodiazepines, barbiturates, morphine, cocaine,
amphetamines, methamphetamines, MDMA, marijuana, and
phencyclidine) with One Step Rapid Test 10 Test Drug Screen
(GIMA, Gessate, Milan, Italy). At baseline, no check for recent
SC’s use was performed because there are no rapid tests for SC
detection available. However, an OF sample was collected at
baseline (before administration) in which no traces of JWH-210,
JWH-122, or other SCs were detected. Tobacco users were asked
to refrain from smoking 2 h before the beginning of the study
session until the end of the session. Adverse events were assessed
during the study sessions and were reported within 24 h after the
self-administration session (24 h by a phone call).
Physiological Effects
Noninvasive systolic blood pressure (SBP), diastolic blood
pressure (DBP), and heart rate (HR) were determined with an
Omron®monitor at baseline and at 10, 20, and 40 min and 1, 2, 3,
and 4 h after administration. The oral temperature was measured
at the same time.
Subjective Effects
Subjective effects were measured at different moments during the
session, using a set of visual analog scales (VASs), the 49-item
Addiction Research Center Inventory (ARCI) form, and the
Evaluation of Subjective Effects of Substances with Abuse
Potential questionnaire (VESSPA-SP).
VAS from “not at all” to “extremely” were used to rate some
items such as “intensity,” “high,” “good effects,” “bad effects,”
“hunger,” “drowsiness,” “dizziness,” “confusion,” “nausea,”
“vomits,” “anxiety,” “aggressiveness,” “hallucinations-seeing of
lights or spots,” “hallucinations-hearing sounds or voices,” and
“hallucinations-seeing animals, things, insects or people”
(Papaseit et al., 2018; Papaseit et al., 2020).
The Spanish validated version of the short-form ARCI is a
true/false 49-item questionnaire, an instrument for the
determination of subjective drug effects (Lamas et al., 1994). It
includes five subscales related to drug sedation (pentobarbital-
chlorpromazine-alcohol group, PCAG), euphoria (morphine-
benzedrine group, MBG), dysphoria and somatic symptoms
(lysergic acid diethylamide group, LSD), intellectual efficiency
and energy (benzedrine group, BG), and d-amphetamine-like
effects (amphetamine, A).
The VESSPA is a questionnaire measuring the changes in
subjective effects caused by different drugs, including stimulants
and psychedelics. It includes six subscales: sedation (S),
psychosomatic anxiety (ANX), changes in perception (CP),
pleasure and sociability (SOC), activity and energy (ACT), and
psychotic symptoms (PS) (González et al., 2015).
The VASs were administered at baseline and at 10, 20, and
40 min and 1, 2, 3, and 4 h after drug administration. ARCI and
VESSPA forms were completed at baseline and at 1, 2, 3, and 4 h
after drug administration.
OF Concentrations
OF was collected with Salivette® tubes at baseline and at 10, 20,
and 40 min and 1, 2, 3, and 4 h after self-administration.
Samples were then centrifuged and frozen at −20°C until
analysis. JWH-210 and JWH-122 were quantified by a
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modified and validated liquid chromatography-mass
spectrometry method (LC-MS/MS) (Pellegrini et al., 2020).
Statistical Analysis
Physiological (SBP, DBP, HR, and cutaneous T) and subjective
(VAS, ARCI, and VESSPA) variables were compared to baseline.
Peak effects (Emax) were determined and the area under the
curve of the effects (AUC0−4 h) was calculated using the
trapezoidal rule by the Pharmacokinetic Functions for
Microsoft Excel (Joel Usansky, Atul Desai, and Diane Tang-
Liu, Department of Pharmacokinetics and Drug Metabolism,
Allergan, Irvine, CA, United States).
For statistical analysis, four consecutive strategies were
performed. Firstly, since subjects selected two different JWH-
210 doses (2 and 3 mg, see Study Design and Treatments), a one-
way analysis of variance (ANOVA) test was conducted to
evidence the possible influence of JWH-210 dose on the
different variables evaluated. The results showed no
statistically significant differences between the two doses.
Hence, the presented statistical analysis was performed
considering data as just one dose. Secondly, Student’s t-test for
unpaired samples was performed to compare Emax and
AUC0−4 h of JHW-122 and JWH-210 of all parameters
calculated. Differences in time to reach peak effects (Tmax)
between JHW-122 and JWH-210 were assessed using a
nonparametric test (Wilcoxon test). Thirdly, a GLM two-way
repeated-measures ANOVA with drug (JWH-122 and JWH-201)
and time (baseline, 10, 20, and 40 min, and 1, 2, 3, and 4 h) as
factors was used to compare the TC of effects between JHW-122
and JWH-210. If significant differences were detected in drug and
time factor, a sequential Bonferroni correction was applied to
correct for multiple comparisons. Fourthly, since no control
group was included, Dunnett’s multiple comparison post hoc
test was conducted to evaluate time effects for each SC (JWH-122
and JWH-2010) comparing the different time points with
baseline values (comparing times 0–10, 0–20, and 0–40 min
and 0–1, 0–2, 0–3, and 0–4 h). Statistical analyses were
performed using PAWS Statistics version 18 (SPSS Inc.,
Chicago, IL, United States). Statistical significance was defined
as p < 0.05.
For OF data, only a descriptive analysis was presented showing
main pharmacokinetics data, e.g., maximum concentration
(Cmax), the time needed to reach the maximum concentration
(Tmax), and AUC0–4. These descriptive parameters were
calculated using the Pharmacokinetic Functions for Microsoft
Excel (Joel Usansky, Atul Desai, and Diane Tang-Liu,
Department of Pharmacokinetics and Drug Metabolism,
Allergan, Irvine, CA, United States). No statistical analysis was




Sixteen polydrug recreational users who reported previous
multiple experiences with cannabis and having used SCs at
least once in their lives were recruited for the study (4 females
and 12 males). Eight subjects were self-administrated by
inhalation 1 mg of JWH-122 (seven males and one female).
They had a mean age of 30 ± 6 years (range: 23–41 years),
weighing 72.95 ± 11.22 kg (range: 60–96 kg), and their mean
body mass index (BMI) was 24.16 ± 4.09 kg/m2 (range:
19.59 ± 32.45 kg/m2). Six participants were current
tobacco smokers.
Eight subjects self-administrated JWH-210 by inhalation. One
male and one female self-administrated a 3 mg dose, and four
males and two females self-administrated 2 mg. They had a mean
age of 31 ± 7 years (range: 22–41 years), weighing 69.63 ±
13.38 kg (range: 54–93 kg), and their mean BMI was 23.26 ±
2.49 kg/m2 (range: 18.29–26.04 kg/m2). Five participants were
current tobacco smokers (Table 1).
Physiological Effects
JWH-122 and JWH-210 effects on physiological variables are
presented in Table 2 and Figure 1.
Self-inhalation of JWH-122 and JWH-210 produced changes
in the physiological variables taken into consideration.
Compared to baseline, JWH-122 self-inhalation produced
statistically significant increases in SBP, DBP, and HR and
JWH-210 self-administration only increased HR. The
maximal effects were observed at 10–20 min following
administration. No statistically significant differences were
found between JWH-122 and JWH-210 in terms of Emax,
AUC0–4 h, or TC points, except for the body temperature
(To) at 1 and 4 h.
Subjective Effects
JWH-122 and JWH-210 effects on subjective variables are
presented in Table 2 and Figure 1.
Self-inhalation of JWH-122 and JWH-210 induced some
changes in subjective effects.
JWH-122 self-inhalation increased VAS “intensity,” “high”
and “good effects,” “hunger,” “somnolence,” “dizziness,”
“confusion,” and “anxiety,” and JWH-210 increased VAS
“intensity” and “high” and “good effects.” For both SCs,
maximal VAS effects were mostly observed 20 min after
intake. Compared to baseline, statistically significant increases
were detected on VAS “intensity,” “high effects,” and “hunger” for
JWH-210 only. When comparing JWH-122 and JWH-210, no
statistically significant differences were found for Emax or
AUC0–4 h. For TC, differences between SCs were only
detected for VAS “hunger” at 4 h.
Self-inhalation of JWH-122 or JWH-210 produced slight
changes in the majority of ARCI questionnaire subscales, with
more marked increases in the subscales sedation (PCAG:
pentobarbital chlorpromazine-alcohol group), euphoria
(MBG), and amphetamine (A). Compared to baseline,
statistically significant increases were found for MBG and A
following self-inhalation of JWH-210.
Compared to baseline, JWH-122 and JWH-210 induced
nonsignificant increases in the VESSPA-SP questionnaire.
When comparing JWH-122 and JWH-210, no statistically
significant differences were found for Emax or AUC0–4 h. For
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TC, differences between SCs were only detected for “ANX”
subscale at 1 h.
Adverse Events
All the selected doses were well tolerated with no relevant adverse
events during the study session. Within 24 h after the self-
administration, one subject who self-administrated JWH-122
reported faintness and three subjects who self-administrated
2 mg of JWH-210 reported 1) hypotension, 2) headache,
dizziness, and vomit, and 3) self-limited mild stabbing chest
pain, respectively. All resolved spontaneously, and the
participants did not need medication or medical assistance.
JWH-122 and JWH-210 OF Concentrations
JWH-122 and JWH-210 OF concentration profiles over time (no
data available from one subject consuming JWH 210) are shown
in Figure 2. JWH-122 OF concentration reached a peak 20 min
after administration with a mean maximum concentration
(Cmax) of 3.88 ng/ml (SD ± 1.23), decreased to a mean value
of 0.62 ng/ml at 1 h, and was not detected after 3 h. Mean
AUC0–4 h was 2.60 ng/mlh (SD ± 0.81). Similarly, JWH-210
OF concentration peaked 20 min after inhalation and was not
detected after 3 h. JWH-210 Cmax was 22.54 ng/ml (SD ± 19.02)
20 min after intake and dropped to a mean value of 4.30 ng/ml at
1 h. AUC0–4 h mean value was 17.18 ng/ml h (SD ± 12.51).
DISCUSSION
To the best of our knowledge, controlled studies on JWH-122 and
JWH-210 pharmacology and pharmacokinetics in humans are
lacking. To date, this is the first study assessing the acute
pharmacological effects and JWH-122 and JWH-210 OF
concentrations in recreational users. In our study, 1 mg JWH-
122 inhalation produced significant acute cardiovascular effects
(SBP, DBP, and HR) with minimal changes in subjective effects
(not statistically significant). In the same naturalistic setting, the
inhalation of a recreational JWH-210 dose (2–3 mg) induced a
pattern of acute effects characterized by a very mild increase of
DBP and HR (not statistically significant) and significant
increases in subjective effects. The global magnitude of
response attributable to JWH-122 and JWH-210 is lower than
that of cannabis. The results obtained can be compared with those
observed in a similar recent study evaluating the effects of UR-144
consumption, as compared to those of THC after inhaled
administration. JWH-122 and UR-144 cardiovascular and
subjective effects were similar in magnitude (La Maida et al.,
2021). UR-144 cardiovascular effects were slightly higher than
those induced by JWH-210, but JWH-210 subjective effects were
higher. When compared to 20 mg THC, all three SCs induced less
intense cardiovascular and subjective effects (La Maida et al.,
2020). JWH-210 results are in agreement with the marked but
transient cardiovascular and euphoric effects described following
the controlled administration by inhalation of JWH-018, one of
the most studied compounds of the JWH family (Theunissen
et al., 2018; Toennes et al., 2018; Theunissen et al., 2019;
Theunissen et al., 2021). Regarding the subjective effects, some
subjects reported moderate to high punctuations in bad effects
after JWH-122 (2 subjects) and JWH-210 (1 subject) intake.
According to the literature, “disliking effects” are a well-known
effect reported mainly by occasional SCs users, while frequent
users more likely reported liking effects (Cooper, 2016). In
addition, neutral response, no response, and no adverse events
are also more likely reported by single or several time SCs users.
During the study, hunger was the most reported nondesirable
effect for all the subjects who self-inhaled SCs. Adverse events
reported 24 h after JWH-122 and JWH-210 self-administration
were limited to slight-mild cardiovascular and/or gastrointestinal
symptoms and headache not requiring emergency attention in
any case. These results are in line with previous retrospective
TABLE 1 | Summary of sociodemographic data and recreative drug use for the participants.
JWH-122 (n = 8) JWH-210 (n = 8)
Mean ± SD (range) Mean ± SD (range)
Sociodemographic data
Female/male 1/7 3/5
Age (years) 30 ± 6 (23–41) 31 ± 7 (22–41)
Weight (kg) 72.95 ± 11.22 (60–96) 69.63 ± 13.38 (54–93)
Height (m) 1.74 ± 0.05 (1.65–1.80) 1.73 ± 0.12 (1.50–1.89)
BMI (kg/m2) 24.16 ± 4.09 (19.59–32.45) 23.26 ± 2.49 (18.29–26.04)
Recreative drug use
Alcohol (g/day) 9.68 ± 10.15 (1.43–32) 15.86 ± 16.72 (2.86–48)
Tobacco (cig/day) 8.10 ± 5.88 (2–16) (n  6) 8.10 ± 5.34 (0.5–15) (n  5)
Cannabis (joints/day) 0.46 ± 0.27 (0.10–0.73) 0.10 ± 0.06 (0.03–0.17)
MDMAa 0.63 ± 1.41 (0–4) 0.0 ± 0.0 (0–0)
Amphetaminea 0.38 ± 0.74 (0–2) 0.13 ± 0.35 (0–1)
NPS/legal highsa 0.75 ± 1.75 (0–5) 0.13 ± 0.35 (0–1)
Cocainea 0.5 ± 1.07 (0–3) 0.0 ± 0.0 (0–0)
Hallucinogensa 0.63 ± 1.41 (0–4) 0.63 ± 1.0 (0–3)
aNumber of times used during the previous month.
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observational studies reporting tachycardia, hypertension, and
other electrocardiographic changes (Hermanns-Clausen et al.,
2013; Hermanns-Clausen et al., 2016).
Both SCs reached their maximal concentrations in OF at
20 min and 15 min after the end of the inhalation. No previous
data exist on JWH-122 and JWH-210 concentrations and TC
of in OF and only limited data are published on the blood
concentrations in some cases of intoxications (Hermanns-
Clausen et al., 2013; Cooper, 2016). In a retrospective
observational case series of subjects presenting to
emergency departments with an analytically confirmed
intake of JWH-210 as the only SC detected in serum
samples, JWH-210 concentrations ranged from 0.18 to
90 ng/ml in serum samples obtained 0.5–16 h after drug use
(median 2 h) with no data about OF samples or other
biological matrices (Hermanns-Clausen et al., 2016). In the
case of UR-144, maximal concentrations were achieved at
20 min (La Maida et al., 2021). For JWH-018, maximal
concentrations in blood and OF were reached at 5 min after
inhalation and the ratio of/serum concentrations was 1.38 at
the median, showing high variability within and between
subjects (Theunissen et al., 2018; Toennes et al., 2018). In
our study, this ratio could not be calculated since we did not
collect blood.
The study has several intrinsic limitations related to its
noncontrolled design (observational design and non-placebo-
TABLE 2 | Summary of significant statistical results on the physiological and subjective effects observed after administration of JWH-122 (n  8) and JWH-210 (n  8).
Parameter Mean ± SD Student’s t-test
comparison effects of
JWH-122 vs. JWH-210
ANOVA comparison time course




JWH-122 JWH-210 T (df = 14) p- Value F (df = 7,98) p- Value TC points JWH-122 JWH-210
Physiological effects
SBP (mmHg) Emax 23.68 ± 14.50 4.87 ± 23.91 1.902 0.078
AUC0-4h 24.66 ± 30.63 7.90 ± 53.90 0.764 0.457
TC 1.094 0.373 NS b NS
DBP (mmHg) Emax 8.81 ± 15.62 11.43 ± 12.85 -0.367 0.719
AUC0-4h 22.16 ± 23.52 18.10 ± 35.66 0.269 0.792
TC 1.951 0.070 NS a, c NS
HR (bpm) Emax 16.37 ± 21.69 -0.37 ± 28.60 1.320 0.208
AUC0-4h −0.34 ± 24.34 −20.85 ± 390.6 1.261 0.228
TC 0.713 0.661 NS a, b a
T (oC) Emax 0.15 ± 0.12 0.05 ± 0.33 0.807 0.433
AUC0-4h 0.23 ± 0.33 −0.06 ± 0.39 1.649 0.121
TC 3.054 0.006 1, 4 NS NS
Subjective effects
Intensity (mm) Emax 2.75 ± 2.66 16.5 ± 27.02) −1.432 0.174
AUC0-4h 1.67 ± 1.98 10.34 ± 18.65 −1.308 0.212
TC 1.801 0.095 NS NS b
High (mm) Emax 5.87 ± 5.98 19.00 ± 27.79 −1.306 0.213
AUC0-4h 3.68 ± 4.70 15.44 ± 26.77 −1.224 0.241
TC 2.283 0.034 NS NS b
Hunger (mm) Emax 6.50 ± 11.13 29.70 ± 26.91 −2.258 0.040
AUC0-4h 10.41 ± 22.42 35.10 ± 30.35 −1.850 0.085
TC 4.189 <0.001 4 NS g
Addiction Research Center Inventory (ARCI) form
MBG (euphoria)
(score)
Emax 1 ± 1.41 1.37 ± 2.38 −0.382 0.708
AUC0-4h 1.25 ± 1.83 2.37 ± 3.74 −7.64 0.457
TC 0.237 0.916 NS NS d
BG (intellectual efficiency and energy) (score) Emax 0.5 ± 0.53 −0.25 ± 1.58 1.271 0.224
AUC0-4h 0.37 ± 0.51 −0.31 ± 1.79 1.043 0.315
TC 2.986 0.026 NS NS NS
A (amphetamine-like effects) (score) Emax 1.25 ± 1.38 0.75 ± 0.88 0.858 0.405
AUC0-4h 1.25 ± 1.38 1.68 ± 2.10 −0.491 0.693
TC 2.350 0.065 NS NS d
Evaluation of subjective effects of substances with abuse potential questionnaire (VESSPA-SP)
ANX (psychosomatic anxiety) (score) Emax 0.12 ± 0.17 0.43 ± 0.28 −2.669 0.018
AUC0-4h 0.19 ± 0.36 0.78 ± 0.68 −2.116 0.053
TC 4.463 0.003 1 NS NS
Emax  peak effects 0–4 h (differences from baseline); AUC0−4 h  area under the curve from 0 to 4 h; TC  temporal course from 0 to 4 h. Emax measured by mmHg [SBP and DBP
(systolic blood pressure and diastolic blood pressure)], bpm [HR (heart rate)], °C [T (cutaneous temperature)], mm [visual analog scale (VAS)], and score Addiction Research Center
Inventory (ARCI) and expressed as mean and standard deviation. For Emax and AUC0−4, a Student’s t-test for independent sample was used (see statistical analysis). A p-value < 0.05
was considered statistically significant. For TC, a ANOVA was used to measured differences between JWH-120 and JWH-210 and statistical differences are presented as “time point”
(p < 0.05) and “time point” (p < 0.01). For Dunnett’s test, statistical differences are presented as “a” p < 0.05, “a” p < 0.01 (times 0–10 m), “b” p < 0.05, “b” p < 0.01 (times 0–20 min), “c”
p < 0.05, “c” p < 0.01 (times 0–40 min), “d” p < 0.05, “d” p < 0.01 (times 0–1 h), “e” p < 0.05, “e” p < 0.01 (times 0–2 h), “f” p < 0.05, “f” p < 0.01 (times 0–3 h), and “g” p < 0.05, “g” p < 0.01
(times 0–4 h) (see statistical analysis). df  degrees of freedom.
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controlled), the relatively small number of participants that
could decrease the study power in the comparisons of the two
SCs, the unknown origin of the substance, the
coadministration with tobacco that could have influenced
some of the cardiovascular effects and adverse events
reported by the participants, the limited number of time-
point measures, and the lack of blood and/or other
biological matrices collection. However, there are a number
of strengths to remark: the participation of males and females
previously experienced with inhaled cannabis and SCs, self-
selection of real-life recreational dosages by the subjects
according to their preferences, the real recreational setting,
and the use of the validated methodology for the evaluation of
acute pharmacological effects and analytic technique to
determine OF concentrations.
CONCLUSION
Our results showed that JWH-122 and JWH-201 exhibit THC
prototypical effects on HR and blood pressure (JWH-122) and
subjective effects (JWH-210) but with a lower intensity. We did
not find relevant toxic effects of JWH-122 and JWH-210,
probably due to the low dose administered. JWH-122 and
JWH-210 were detected in OF after dosing in naturalistic
conditions, confirming OF as a potential biological matrix to
document SC use. Further research with a larger sample and
controlled studies are needed to better define the acute
pharmacological and health risk profile of JWH-122, JWH-
210, and other SCs and the relevance of OF testing. This
study could serve as a blueprint for follow-up research on
this topic.
FIGURE 1 | Summary of the course of main physiological (systolic blood pressure and heart rate) and subjective effects (intensity and high in visual analog scales)
observed after administration of JWH-122 (n  8) and JWH-210 (n  8). ○ JWH-122; □ JWH-210; values are mean and standard error. Symbols indicate a significant
difference to baseline: for JWH-122 * (p < 0.05); for JWH-210 + (p < 0.05), + (p < 0.05).
FIGURE 2 | Time course of JWH-122 (n  8) and JWH-210 (n  7)
concentrations in oral fluid. ○ JWH-122; □ JWH-210; values are mean and
standard error.
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